0001209191-19-056038.txt : 20191112 0001209191-19-056038.hdr.sgml : 20191112 20191112163828 ACCESSION NUMBER: 0001209191-19-056038 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191112 FILED AS OF DATE: 20191112 DATE AS OF CHANGE: 20191112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Manning Paul B CENTRAL INDEX KEY: 0001494695 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38135 FILM NUMBER: 191210181 MAIL ADDRESS: STREET 1: 200 GARRETT STREET SUITE S CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001685071 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813858961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 BUSINESS PHONE: 919-806-4487 MAIL ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 FORMER COMPANY: FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20160919 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-12 1 0001685071 Dova Pharmaceuticals Inc. DOVA 0001494695 Manning Paul B 200 GARRETT STREET, SUITE S CHARLOTTESVILLE VA 22902 1 0 1 0 Common Stock 2019-11-12 4 U 0 12979016 27.50 D 0 D Common Stock 2019-11-12 4 U 0 1783226 27.50 D 0 I By LLC Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship. These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. /s/ Mark Ballantyne, Attorney-in-Fact 2019-11-12